OPN 2853
Alternative Names: OPN-2853; PLX-2853Latest Information Update: 02 Feb 2024
At a glance
- Originator Plexxikon
- Developer Daiichi Sankyo Company; Opna Bio; University of Birmingham
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Myelofibrosis
- Discontinued Acute myeloid leukaemia; Graft-versus-host disease; Gynaecological cancer; Haematological malignancies; Myelodysplastic syndromes; Ovarian cancer; Prostate cancer; Solid tumours
Most Recent Events
- 02 Feb 2024 OPN 2853 is available for licensing as of 24 Jan 2024 (https://www.opnabio.com/pipeline/)
- 14 Apr 2023 Efficacy and adverse event data from phase Ib/IIa trial in Ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 25 Jan 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO)